| Unadjusted model | Adjusted model | ||
---|---|---|---|---|
 | HR (95% CI) | p value | HR (95% CI) | p value |
Whole population (N=1593) | Â | Â | Â | Â |
Continuous per 1 unit increase | 1.15 (1.11-1.19) | <0.001 | 1.09 (1.05-1.14) | <0.001 |
Tertile 1 (<5.5Â mg/dL) | Reference | -- | Reference | -- |
Tertile 2 (5.6-7.0Â mg/dL) | 0.96 (0.81-1.14) | 0.657 | 0.94 (0.78-1.12) | 0.474 |
Tertile 3 (>7.0Â mg/dL) | 1.52 (1.29-1.78) | <0.001 | 1.28 (1.06-1.54) | 0.009 |
Men (N=897, 56.3%) | Â | Â | Â | Â |
Continuous per 1 unit increase | 1.14 (1.09-1.20) | <0.001 | 1.11 (1.05-1.18) | <0.001 |
Tertile 1 (<5.9Â mg/dL) | Reference | -- | Reference | -- |
Tertile 2 (5.9-7.4Â mg/dL) | 0.99 (0.79-1.24) | 0.914 | 1.05 (0.82-1.33) | 0.720 |
Tertile 3 (>7.4Â mg/dL) | 1.71 (1.38-2.12) | <0.001 | 1.49 (1.17-1.91) | 0.001 |
Women (N=696, 43.7%) | Â | Â | Â | Â |
Continuous per 1 unit increase | 1.16 (1.10-1.23) | <0.001 | 1.05 (0.98-1.12) | 0.186 |
Tertile 1 (<5.1Â mg/dL) | Reference | -- | Reference | -- |
Tertile 2 (5.1-6.5Â mg/dL) | 1.28 (0.99-1.67) | 0.064 | 0.97 (0.73-1.28) | 0.834 |
Tertile 3 (>6.5Â mg/dL) | 1.64 (1.27-2.12) | <0.001 | 1.03 (0.77-1.39) | 0.836 |